MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)

Myriad Genetics showed investors an adjusted EBITDA target of $37 million to $49 million for 2026. Months later, the Company suspended adjusted EBITDA guidance entirely -- leaving MYGN shareholders to absorb the loss.

NEW YORK--(BUSINESS WIRE)--On May 5, 2026, Myriad Genetics (NASDAQ: MYGN) reaffirmed adjusted EBITDA of $37 million to $49 million and adjusted gross margin of 68% to 69% for full-year 2026. Roughly three months later, the adjusted EBITDA range was suspended outright and MYGN shares dropped. If you held Myriad Genetics stock and lost money, you are encouraged to submit your loss information now. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

Two sets of numbers sat side by side. The adjusted profitability target was $37 million to $49 million. The Company's Form 10-Q for the quarter ended March 31, 2026, filed May 6, 2026, reported net cash used in operating activities of $15.7 million, with trade accounts receivable of $123.8 million versus $115.3 million at December 31, 2025.

For the second quarter of 2026, Myriad Genetics reported revenue of approximately $190.7 million and a wider-than-expected adjusted loss, with gross margins declining. The reaffirmed adjusted EBITDA range was subsequently suspended. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors.

Myriad Genetics shareholders who suffered losses may request a free case evaluation here or call [phone].

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the MYGN Investigation

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Myriad Genetics made materially false or misleading statements regarding its adjusted profitability and margin outlook for 2026. After the Company suspended its adjusted EBITDA guidance and reported weaker results, the stock price declined.

Q: Who is eligible to participate in the MYGN investigation? A: Investors who purchased MYGN stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: Who is conducting the MYGN investigation? A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased MYGN securities. The firm is nationally recognized and has recovered hundreds of millions of dollars for aggrieved investors.

Q: What do MYGN investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [e-mail] or [phone].

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my MYGN shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought MYGN and sold at a loss may still participate in the investigation.

Q: What if my MYGN losses are small -- is it still worth contacting a lawyer? A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost. Securities investigations and any resulting actions are generally handled on a contingency basis -- no retainer and no out-of-pocket costs.

Attorney Advertising. Prior results do not guarantee similar outcomes.